The Biotechnology Institute named Invitrogen's Peter Leddy to its board of directors, the organization said last week.
Leddy is senior vice-president of human resources, a position he's held since July 2005. Prior to Invitrogen, Leddy spent five years with Dell in several management positions, most recently vice-president of human resources for Americas Operations.
He received his BA in psychology from Creighton University and his MS and PhD in industrial/organizational psychology from the Illinois Institute of Technology.
Sigma-Aldrich has extended the term of employment of Chairman David Harvey for a one-year term beginning on the date of the first annual general meeting following Jan. 1, 2006, and terminating on the second annual general meeting following Jan. 1, 2006.
Cambridge, UK-based NextGen Group has appointed Geoff Alms as sales director for North America and Gareth Thomson as head of marketing, the company said last week.
Alms came to NextGen Science from Upstate, a division of Serologicals, where he was employed as director of sales for drug discovery for the North America region. Alms completed his PhD and postdoctoral studies in pharmacology at the University of Virginia.
Along with Alms, three salesmen were appointed to create a technically qualified sales team in the US.
Prior to NextGen, Thomson was senior marketing manager for Affymetrix UK. He was also at Amersham-Pharmacia Biotech, now GE Healthcare. He holds a BSc in biological sciences from Salford University in Manchester, England.
Enzo Biochem appointed Carl Balezentis as president of Enzo Life Sciences, its wholly owned subsidiary, the company said last week.
Formerly, Balezentis was chief executive officer of Lark Technologies prior to its acquisition by Genaissance Pharmaceuticals. After the acquisition, he joined Genaissance as a senior vice president. Prior to Lark, he was director of business development at Sigma-Aldrich's life sciences division. He was vice president of sales and marketing at Genosys Biotechnologies prior to its acquisition by Sigma-Aldrich.
Balezentis was a director of marketing at Perceptive Scientific Instruments before its acquisition by International Remote Imaging Systems, and a group leader for human identity products at Applied Biosystems.
Nonlinear Dynamics has appointed Christian Stahlberg as applications specialist, the company said last week.
Stahlberg comes to Nonlinear from GE Healthcare where he was most recently managed the DeCyder Extended Data Analysis project.
Cellomics to Provide Service for Beckman Coulter's Abandoned HCS Products
Cellomics, a unit of Fisher Biosciences, said this week that it will provide maintenance and service support for customers of Beckman Coulter's high-content screening systems.
The agreement covers Beckman Coulter's Cell Lab IC 100 Image Cytometer and EIDAQ 100 High-Throughput Microscopy System. Late last year, the company decided to stop marketing its HCS products, but planned to continue support for its existing customers (see BioCommerce Week 11/24/2005).
"Our primary goal in reaching this agreement was to provide ongoing support for our customers," Karen Bezold, director of research Cytometry at Beckman Coulter, said in a statement.
Beckman Coulter said it plans to continue to focus its research cytometry business on flow cytometry and particle characterization.
PerkinElmer, Israeli Med Center to Create Neonatal Screening Program
Israel's Chaim Sheba Medical Center has selected PerkinElmer's nenonatal screen technology to create a national newborn screening program, the company said last week.
The neonatal screening initiative will be built around the company's AutoDELFIA automatic immunoassay system. PerkinElmer will deliver multiple AutoDELFIA units as well as reagents and equipment.
Under the agreement, PerkinElmer will provide the center with instruments, reagents, scientific expertise, and an informatics system to enhance its neonatal screening and data-management capabilities.
Israel is following a mandate set by the Medical Research Infrastructure Development and Health Services Fund to substantially expand its newborn screening program to cover the entire population and to increase the number of tests screened for indications of disease.
Invitrogen Shares Upgraded
Investment bank Bear Stearns upgraded Invitrogen's stock to "Outperform" from "Peer Perform" last week.
Invitrogen's shares climbed 2.9 percent to close at $64.84 on Friday, the day of the upgrade. Invitrogen's shares have since pulled back to $63.87.
Eppendorf Affiliate Licenses Ingenuity's Pathway Analysis Software
An Eppendorf affiliate has licensed Ingenuity's Pathways Analysis Software, the informatics company said this week.
Eppendorf Array Technologies will use the software for internal development and special projects for "key accounts and service providers."
Financial terms were not disclosed.
Clinical Data to Raise $17M from Stock Sale
Clinical Data this week said it stands to gain $17 million from the sale of approximately 1.5 million shares and warrants of its common stock to certain undisclosed institutional and other investors.
The company did not discuss when it expects the transactions to close.
Clinical Data President and CEO Drew Fromkin said that the extra capital will strengthen his company's ability to commercialize molecular diagnostics; continue its Phase III clinical development of the antidepressant Vilazodone and help it spin out the vilazodone business into a new company called Precigen Therapeutics; and to enhance its genetic services and analysis business.
The company said it will also use some of the cash to pay for a restructuring it announced in March.